Drug profile · INN
crofelemer
MYTESI
crofelemer (MYTESI) is a cystic fibrosis transmembrane conductance regulator inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — crofelemer
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
crofelemer (MYTESI) is a cystic fibrosis transmembrane conductance regulator inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Cystic fibrosis transmembrane conductance regulator inhibitor
Primary target: Anoctamin-1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Frequently asked questions
What is crofelemer?
crofelemer (MYTESI) is a cystic fibrosis transmembrane conductance regulator inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for crofelemer?
MYTESI is a marketed brand name for crofelemer. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of crofelemer?
crofelemer has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.